Sulfamides (i.e., Hnh-(o=)s(=o)-hnh, Wherein Substitution May Be Made For Hydrogen Only) Patents (Class 564/79)
  • Patent number: 10160742
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: December 25, 2018
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: Ryan C. Clark, Yen Truong, Nicholas Stock, Jason Jacintho
  • Patent number: 9018260
    Abstract: Novel indansulfamide derivatives or a pharmaceutically acceptable salt thereof such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, N-[(1S)-2,2,4,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (+)-N-(2,2,4,6,7-pentafluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, have an action of improving Seizure Severity Index (Score) in mice kindling model. Thus the compounds or the salt thereof are expected as a drug for treating epilepsy.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: April 28, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yuji Kazuta, Toru Watanabe, Keiichi Sorimachi, Minako Saito, Yoichi Kita, Toshiaki Tanaka, Hiroyuki Higashiyama, Takahisa Hanada, Tetsuyuki Teramoto, Takashi Kosasa, Yukio Ishikawa
  • Patent number: 8980442
    Abstract: There are provided an aromatic monoamine derivative having a fluorene structure-containing organic group and an aromatic hydrocarbon group-containing organic group, and an organic electroluminescent element containing an organic thin film layer composed of a single layer or plural layers while including at least a light emitting layer, the organic thin film layer being between a cathode and an anode, wherein at least one layer of the organic thin film layer, particularly a hole transport layer, contains the aromatic amine derivative alone or as a component of a mixture. An organic electroluminescent element which maintains high luminous efficiency even if exposed to a high temperature environment, and has a low driving voltage and a long emission lifetime, and an aromatic amine derivative capable of realizing the organic electroluminescent element are provided.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: March 17, 2015
    Assignee: Mitsui Chemicals, Inc.
    Inventors: Nobuhiro Yabunouchi, Tomoki Kato, Takahiro Fujiyama, Yoshiyuki Totani
  • Publication number: 20150025042
    Abstract: Disclosed are compounds of formulae (I), (III), (IV), (VII), (X), (XI), (XII), (XIII) and (XIV), wherein the variables are as defined in the claims, and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: December 16, 2013
    Publication date: January 22, 2015
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: Shoujun Chen, Keizo Koya, Zachary Demko, Lijun Sun
  • Publication number: 20150005493
    Abstract: The invention provides methods and intermediates that are useful for preparing a compound of formula I: and salts thereof.
    Type: Application
    Filed: September 3, 2014
    Publication date: January 1, 2015
    Inventors: Richard POLNIASZEK, Steven PFEIFFER, Richard YU, Aaron CULLEN, Eric DOWDY, Duong TRAN, Kenneth KENT, Zhongxin ZHOU, Doug CORDEAU, Leah EASTON-SCOTT
  • Publication number: 20140371319
    Abstract: Novel indansulfamide derivatives or a pharmaceutically acceptable salt thereof such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, N-[(1S)-2,2,4,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (+)-N-(2,2,4,6,7-pentafluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, have an action of improving Seizure Severity Index (Score) in mice kindling model. Thus the compounds or the salt thereof are expected as a drug for treating epilepsy.
    Type: Application
    Filed: June 17, 2013
    Publication date: December 18, 2014
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yuji Kazuta, Toru Watanabe, Keiichi Sorimachi, Minako Saito, Yoichi Kita, Toshiaki Tanaka, Hiroyuki Higashiyama, Takahisa Hanada, Tetsuyuki Teramoto, Takashi Kosasa, Yukio Ishikawa
  • Publication number: 20140315879
    Abstract: The present invention relates to sulfonamide derivatives, of formula (I): or a pharmaceutically acceptable salts thereof, wherein X, Z, R1a, R1b, R2, R3, R4 and R5 are as defined in the description, and to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. The compounds of formula (I) are Nav1.7 inhibitors useful in the treatment of a wide range of disorders, particularly pain.
    Type: Application
    Filed: December 6, 2012
    Publication date: October 23, 2014
    Applicant: PFIZER LIMITED
    Inventors: David James Rawson, Robert Ian Storer, Nigel Alan Swain
  • Patent number: 8859590
    Abstract: Inhibitors of BACE1 and compositions containing them are described. Use of the inhibitors and compositions containing them to treat Alzheimer's disease are described.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: October 14, 2014
    Assignee: Purdue Research Foundation
    Inventor: Arun K. Ghosh
  • Patent number: 8808742
    Abstract: This invention relates to compositions, methods for preparing the compositions and methods for treating or preventing diseases, comprising administering the compositions.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: August 19, 2014
    Assignee: Ardea Biosciences, Inc.
    Inventors: Barry D. Quart, Colin Edward Rowlings
  • Patent number: 8778838
    Abstract: The present invention relates to aqueous concentrate formulations for plant protection comprising: 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2H)pyrimidinyl]-4-fluoro-N-[[methyl(1-methylethyl)amino]sulfonyl]benzamide in the form of its anhydrate; N-(phosphonomethyl)glycine in the form of its free acid, in the form of the ammonium salt or a substituted ammonium salt or a mixture thereof; at least two different non-ionic surfactants with at least one of them comprising an ethylene oxide polymer moiety or an ethylene oxide/C3-C4-alkylene oxide block copolymer moiety, and water; wherein the pH-value of the formulation is below 6.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: July 15, 2014
    Assignee: BASF SE
    Inventors: Michael Krapp, Wolfgang Gregori, Sven Adam, Klaus Kolb, Juergen Jakob, Bernd Sievernich, Joerg Steuerwald, Steven Bowe, Joseph Zawierucha, Rex Liebl
  • Patent number: 8653002
    Abstract: The present invention relates to aqueous suspension concentrate formulation for plant protection comprising: 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2H)pyrimidinyl]-4-fluoro-N-[[methyl(1-methylethyl)amino]sulfonyl]benzamide in the form of its crystalline anhydrate; at least one non-ionic surfactant selected from polyoxyethylene-polyoxy-C3-C4-alkylene block copolymers; at least one anionic surfactant comprising at least one arylsulfonate group; and water; wherein the pH value of the formulation is in the range of 3 to 7.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: February 18, 2014
    Assignee: BASF SE
    Inventors: Michael Krapp, Wolfgang Gregori, Klaus Kolb, Bernd Sievernich, Heidi Emilia Saxell, Joerg Steuerwald, Steven Bowe, Rex Liebl, Terrance M. Cannan
  • Publication number: 20140024636
    Abstract: Provided is a sulfamide derivative having an adamantyl group represented by the following Formula 1, or a pharmaceutically acceptable salt thereof. The sulfamide derivative suppresses the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1), and is useful in the treatment of various diseases that are mediated by 11?-HSD1.
    Type: Application
    Filed: March 30, 2012
    Publication date: January 23, 2014
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Ki Young Kim, Jin Hee Ahn, Seung Kyu Kang, Sang Dal Rhee, Myung Ae Bae, Sung Hoon Ahn, Hee Youn Kim, Won Hoon Jung, Nam Sook Kang
  • Patent number: 8609720
    Abstract: Disclosed are compounds of formulae (I), (III), (IV), (VII), (X), (XI), (XII), (XIII) and (XIV), wherein the variables are as defined in the claims, and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: December 17, 2013
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Shoujun Chen, Keizo Koya, Zachary Demko, Lijun Sun
  • Patent number: 8609849
    Abstract: Pharmaceutical compositions of the invention include hydroxylated sulfamide derivatives having a disease-modifying action in the treatment of diseases associated with excitotoxicity and accompanying oxidative stress that include epilepsy, Alzheimer's disease, and any neurodegenerative disease involving glutamate toxicity.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: December 17, 2013
    Assignees: Fox Chase Chemical Diversity Center, Inc., Advanced Neural Dynamics, Inc.
    Inventors: Garry Robert Smith, Douglas E. Brenneman, Allen B. Reitz, Yan Zhang, Yanming Du
  • Patent number: 8609076
    Abstract: The present invention relates to the use of polyols of formula (I): or a salt thereof, for preventing the hair from breaking. The invention also relates to a cosmetic composition comprising at least one such polyol or a salt thereof, in a cosmetically acceptable medium, and also to a cosmetic hair treatment process using the said composition.
    Type: Grant
    Filed: May 13, 2005
    Date of Patent: December 17, 2013
    Assignee: L'Oreal
    Inventors: Frederic Leroy, Michel Philippe, Philippe Barbarat, Christian Blaise
  • Publication number: 20130317001
    Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: May 21, 2013
    Publication date: November 28, 2013
    Applicants: XENON PHARMACEUTICALS INC., GENENTECH, INC.
    Inventors: Jean-Christophe Andrez, Sultan Chowdhury, Shannon Marie Decker, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Jun Li, Daniel F. Ortwine, Brian Safina, Tao Sheng, Shaoyi Sun, Daniel P. Sutherlin, Michael Scott Wilson, Alla Yurevna Zenova
  • Publication number: 20130317000
    Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: May 21, 2013
    Publication date: November 28, 2013
    Applicants: XENON PHARMACEUTICALS INC., GENENTECH, INC
    Inventors: Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Daniel Ortwine, Brian Safina, Shaoyi Sun, Daniel P. Sutherlin, Alla Yurevna Zenova
  • Patent number: 8586733
    Abstract: The present invention includes methods/processes and intermediates for preparing compounds having structural Formula (I): wherein X is alkyl, substituted alkyl, alkenyl, substituted alkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl, or substituted heteroalkenyl.
    Type: Grant
    Filed: July 29, 2009
    Date of Patent: November 19, 2013
    Assignee: Senomyx, Inc.
    Inventors: Catherine Tachdjian, Donald S. Karanewsky, Xiao-Qing Tang, Qing Chen, Peter Leeming, Tayyab Rashid, Daniel Levin
  • Patent number: 8569378
    Abstract: The present invention provides a p27 protein inducing agent comprising a compound represented by general formula (11) below or pharmaceutically acceptable salt thereof as an active ingredient: wherein G1, G2, G3 and G8 are each independently selected from —N? etc., Ring G6 is selected from divalent aryl etc., A is selected from amino etc., G4 is selected from oxygen etc., G5 is selected from oxygen etc., G7 is selected from —CH2— etc., and R2 is selected from C1-6 alkyl etc.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: October 29, 2013
    Assignees: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Toshiyuki Sakai, Hitoshi Iikura, Ikumi Hyoudoh, Toshihiro Aoki, Noriyuki Furuichi, Masayuki Matsushita, Fumio Watanabe, Sawako Ozawa, Masahiro Sakaitani, Pil-Su Ho, Yasushi Tomii, Kenji Takanashi, Naoki Harada
  • Publication number: 20130253022
    Abstract: Pharmaceutical compositions of the invention include fluorinated sulfamide derivatives having a disease-modifying action in the treatment of diseases associated with excitotoxicity and accompanying oxidative stress that include epilepsy, Alzheimer's disease, Parkinson's disease, Huntington's disease, heavy metal toxicity and any neurodegenerative disease involving glutamate toxicity.
    Type: Application
    Filed: November 18, 2011
    Publication date: September 26, 2013
    Applicants: FOX CHASE CHEMICAL DIVERSITY CENTER, INC., ADVANCED NEURAL DYNAMICS, INC.
    Inventors: Garry Robert Smith, Douglas E. Brenneman, Allen B. Reitz, Yan Zhang, Yanming Du
  • Patent number: 8497396
    Abstract: The invention provides methods and intermediates that are useful for preparing a compound of formula I: and salts thereof.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: July 30, 2013
    Assignee: Gilead Sciences, Inc.
    Inventors: Richard Polniaszek, Steven Pfeiffer, Richard Yu, Aaron Cullen, Eric Dowdy, Duong Tran, Kenneth Kent, Zhongxin Zhou, Doug Cordeau, Leah Easton
  • Publication number: 20130184342
    Abstract: The technology described herein relates to methods of inducing cell death. The technology described herein further relates to treating conditions including cancers and autoimmune diseases comprising administering inhibitors of double strand break repair. Also described herein are inhibitors of double strand break repair and methods of screening for such inhibitors.
    Type: Application
    Filed: March 13, 2013
    Publication date: July 18, 2013
    Applicant: THE JACKSON LABORATORY
    Inventor: THE JACKSON LABORATORY
  • Patent number: 8389764
    Abstract: The invention relates to compounds of the formula I as defined herein, which are inhibitors of activated thrombin-activatable fibrinolysis inhibitor. The compounds of the formula I are suitable for manufacturing medicaments for the prophylaxis, secondary prevention and therapy of one or more disorders which are associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: March 5, 2013
    Assignee: Sanofi
    Inventors: Christopher Kallus, Mark Broenstrup, Werngard Czechtizky, Andreas Evers, Markus Follmann, Nis Halland, Herman Schreuder
  • Publication number: 20120302546
    Abstract: Pharmaceutical compositions of the invention include sulfamide derivatives having a disease-modifying action in the treatment of diseases associated with excitotoxicity and accompanying oxidative stress that include epilepsy, Alzheimer's disease, and any neurodegenerative disease involving glutamate toxicity.
    Type: Application
    Filed: February 3, 2011
    Publication date: November 29, 2012
    Applicants: FOX CHASE CHEMICAL DIVERSITY CENTER, INC., ADVANCED NEURAL DYNAMICS, INC.
    Inventors: Garry Robert Smith, Douglas Eric Brenneman, Allen B. Reitz, Yanming Du
  • Publication number: 20120269804
    Abstract: The present invention relates to substituted benzosulphonamide compounds of general formula (I): in which R1, R2, R3, R4, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: October 7, 2010
    Publication date: October 25, 2012
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Marion Hitchcock, Ingo Hartung, Florian Pühler
  • Publication number: 20120270917
    Abstract: Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being capable of interaction with the M2 protein.
    Type: Application
    Filed: July 30, 2010
    Publication date: October 25, 2012
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: William F. DeGrado, Jun Wang
  • Publication number: 20120263714
    Abstract: The present invention relates to substituted halophenoxybenzamide derivative compounds of general formula (I) in which R1, R2, R3, R3a, R4, R5, R6, Ra, Rb, Rc, and X are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: October 12, 2010
    Publication date: October 18, 2012
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Marion Hitchcock, Ingo Hartung, Florian Pühler, Gerhard Siemeister, Roland Neuhaus
  • Patent number: 8283478
    Abstract: The present invention is directed to novel process for the preparation of sulfonylimine and sulfamide derivatives.
    Type: Grant
    Filed: April 19, 2006
    Date of Patent: October 9, 2012
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ahmed F. Abdel-Magid, Steven J. Mehrman
  • Patent number: 8263806
    Abstract: The invention relates to methods for producing sulfonamides of formula I, wherein the variables have the designations cited in the description, by reacting m-nitro-benzoic acid chlorides of formula II with aminosulfons of formula III, under the influence of B equivalents of base IV. Said method is characterized in that, during step a) the aminosulfon of formula III is reacted with B1 equivalents of base IV, and during step b), the reaction mixture resulting from step a) is reacted with m-nitro-benzoic acid chlorides of formula II and B2 equivalents of base IV; B, B1 and B2 having the designations cited in the description.
    Type: Grant
    Filed: November 23, 2006
    Date of Patent: September 11, 2012
    Assignee: BASF SE
    Inventors: Thomas Schmidt, Joachim Gebhardt, Sandra Löhr, Michael Keil, Jan Hendrik Wevers, Michael Rack, Guido Mayer, Axel Pleschke
  • Publication number: 20120213758
    Abstract: The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders.
    Type: Application
    Filed: April 27, 2012
    Publication date: August 23, 2012
    Applicant: DeCODE Genetics enf
    Inventors: Jasbir SINGH, Mark E. GURNEY, Alex BURGIN, Alexander KISELYOV, Munagala RAO, Timothy HAGEN
  • Patent number: 8188312
    Abstract: The present invention is related to acyclic sulfamide derivatives, useful for the manufacture of a medicament for satiety induction and ingestion control, corporal fat modulation and lipidic metabolism regulation and for the manufacture of a medicament for the treatment or prevention of diabetes and cardiovascular diseases. The acyclic sulfamide derivatives are also useful for cosmetic use.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: May 29, 2012
    Assignees: Fundacion Imabis. Instituto Mediterraneo para el Avance de la Biotecnologia y la Investigacion Sanitaria, Consejo Superior de Investigaciones Cientificas
    Inventors: Fernando Antonio Rodriguez de Fonseca, Manuel Macias Gonzalez, Javier Pavon Moron, María Pilar Goya-Laza, Juan Antonio Paez Prosper, Carolina Cano Ramos
  • Patent number: 8183272
    Abstract: Compounds exhibiting calcium receptor antagonist activity that are safe and orally administrable having Formula (I) or pharmaceutically acceptable salts thereof:
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: May 22, 2012
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Akira Nakao, Kentoku Gotanda, Kazumasa Aoki, Shimpei Hirano, Yoshiharu Hiruma, Takeshi Shiiki
  • Publication number: 20110245494
    Abstract: The present invention includes methods/processes and intermediates for preparing compounds having structural Formula (I): wherein X is alkyl, substituted alkyl, alkenyl, substituted alkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl, or substituted heteroalkenyl.
    Type: Application
    Filed: July 29, 2009
    Publication date: October 6, 2011
    Applicant: SENOMYX, INC.
    Inventors: Catherine Tachdjian, Donald S. Karanewsky, Xiao-Qing Tang, Qing Chen, Peter Leeming, Tayyab Rashid, Daniel Levin
  • Publication number: 20110144146
    Abstract: The present invention relates to an aminomethyl substituted bicyclic aromatic compound of the formula I wherein Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered C-bound heteroaromatic radical comprising as ring member 1, 2 or 3 heteroatoms which are, independently of each other, selected from O, S and N, and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, 0 and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR8, where R8 is H, C1-C4-alkyl, fluorinated C1-C4-alkyl, C1-C4-alkylcarbonyl or fluorinated C1-C4-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents Ra, wherein the variable Ra has the meanings given in the claims and in the description; X is a covalent bond or N—R2, CHR2, CHR2CH2, N or C—R2; Y is N—R2a, CHR2a, CHR2aCH2 or CHR2aCH2CH2; is a single bond o
    Type: Application
    Filed: October 14, 2005
    Publication date: June 16, 2011
    Inventors: Karla Drescher, Andreas Haupt, Liliane Unger, Sean C. Turner, Wilfried Braje, Roland Grandel
  • Publication number: 20110044918
    Abstract: The present invention relates to the cosmetic use of a compound of formula (I) and also the cosmetically acceptable salts thereof, solvates thereof and isomers thereof, for non-therapeutic skincare.
    Type: Application
    Filed: October 29, 2010
    Publication date: February 24, 2011
    Applicant: L'OREAL
    Inventors: Xavier Marat, Benoit Muller
  • Publication number: 20110039819
    Abstract: The present invention relates to substituted phenoxybenzamide compounds of general formula (I): in which R1, R2, R3, R4, R5, X, R6 and q are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: April 9, 2009
    Publication date: February 17, 2011
    Inventors: Marion Hitchcock, Ingo Hartung
  • Patent number: 7842836
    Abstract: This invention concerns N-(ortho phenylaminoaryl), N?-alkyl sulfamides which are inhibitors of MEK and are useful in the treatment of cancer and other hyperproliferative diseases.
    Type: Grant
    Filed: April 11, 2007
    Date of Patent: November 30, 2010
    Assignee: Ardea Biosciences
    Inventors: Shunqi Yan, Jean-Michel Vernier, Zhi Hong
  • Publication number: 20100256366
    Abstract: The invention provides methods and intermediates that are useful for preparing a compound of formula I: and salts thereof.
    Type: Application
    Filed: April 1, 2010
    Publication date: October 7, 2010
    Inventors: Richard Polniaszek, Steven Pfeiffer, Richard Yu, Aaron Cullen, Eric Dowdy, Duong Tran, Kenneth Kent, Zhongxin Zhou, Doug Cordeau, Leah Easton
  • Publication number: 20100228054
    Abstract: The invention relates to methods for producing sulfonamides of formula I, wherein the variables have the designations cited in the description, by reacting m-nitro-benzoic acid chlorides of formula II with aminosulfons of formula III, under the influence of B equivalents of base IV. Said method is characterised in that, during step a) the aminosulfon of formula III is reacted with B1 equivalents of base IV, and during step b), the reaction mixture resulting from step a) is reacted with m-nitro-benzoic acid chlorides of formula II and B2 equivalents of base IV; B, B1 and B2 having the designations cited in the description.
    Type: Application
    Filed: November 23, 2006
    Publication date: September 9, 2010
    Applicant: BASF SE
    Inventors: Michael Keil, Joachim Gebhardt, Michael Rack, Guido Mayer, Thomas Schmidt, Jan Hendrik Wevers, Sandra Lohr, Axel Pleschke
  • Publication number: 20100222317
    Abstract: The present invention relates to compounds of formula (I); and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof, as GIyT1 inhibitors for treating neurological and psychiatric disorders.
    Type: Application
    Filed: November 23, 2006
    Publication date: September 2, 2010
    Inventors: Wesley Peter Blackaby, Richard Thomas Lewis, Elizabeth Mary Naylor
  • Publication number: 20100174113
    Abstract: The invention relates to a process for preparing aromatic sulphonylimides, to the sulphonylimides obtained, and to the use thereof as salt of an electrolyte. The sulphonylimides correspond to the formula [R—SO2—N—SO2R?]rM (I). R? is an ArZL- group. R? is a perfluoroalkyl group or an ArZL- group. Z is an S, SO or SO2 group. L is a —(CF2)n—CFRf— group. n is 0 or 1; Rf represents F or a C1 to C8 perfluoroalkyl group; Ar is an aromatic group. M represents H, an alkali metal cation, an alkaline earth metal cation, a trivalent or tetravalent metal cation, or an organic cation. The process consists in preparing a compound RSO2N(R?)SO2R? from RSO2F, and in replacing the group R? by nucleophilic substitution reaction so as to obtain the compound (I), R? being a benzyl or trimethylsilyl group.
    Type: Application
    Filed: July 17, 2007
    Publication date: July 8, 2010
    Applicants: INSTITUT NATIONAL POLYTECHNIQUE DE GRENOBLE, ERAS-LABO, UNIVERSITE CLAUDE BERNARD LYON 1
    Inventors: Jean-Yves Sanchez, Bernard Langlois, Maurice Medebielle, Fabien Toulgoat, Fannie Alloin, Elie Paillard, Cristina Iojoiu
  • Patent number: 7687666
    Abstract: Processes for preparing amino alcohols or salts thereof and sulfonamide substituted alcohol compounds are provided. Desirably, the sulfonamide substituted alcohol compounds are heterocyclic sulfonamide trifluoroalkyl-substituted alcohol compounds or phenyl sulfonamide trifluoroalkyl-substituted alcohol compounds.
    Type: Grant
    Filed: February 15, 2007
    Date of Patent: March 30, 2010
    Assignee: Wyeth
    Inventors: Anita Wai-Yin Chan, Jianxin Ren, Mousumi Ghosh, Arkadiy Rubezhov, Panolil Raveendranath, Joseph Zeldis
  • Publication number: 20090221710
    Abstract: The present invention is related to acyclic sulfamide derivatives, useful for the manufacture of a medicament for satiety induction and ingestion control, corporal fat modulation and lipidic metabolism regulation and for the manufacture of a medicament for the treatment or prevention of diabetes and cardiovascular diseases. The acyclic sulfamide derivatives are also useful for cosmetic use.
    Type: Application
    Filed: January 26, 2007
    Publication date: September 3, 2009
    Inventors: Fernando Antonio Rodriguez De Fonseca, Manuel Macias Gonzalez, Javier Pavon Moron, Maria Pilar Goya-Laza, Juan Antonio Paez Prosper, Carolina Cano Ramos
  • Publication number: 20090182141
    Abstract: The present invention is directed to novel processes for the preparation of sulfamide derivatives, useful in the treatment of epilepsy and related disorders.
    Type: Application
    Filed: January 6, 2009
    Publication date: July 16, 2009
    Inventors: Ahmed Abdel-Magid, Steven J. Mehrman, Caterina Ferraro
  • Publication number: 20090176996
    Abstract: The present invention is directed to novel processes for the preparation of sulfamide derivatves, useful in the treatment of epilepsy and related disorders.
    Type: Application
    Filed: January 7, 2009
    Publication date: July 9, 2009
    Inventors: Ahmed Abdel-Magid, Steven J Mehrman, Caterina Ferraro
  • Patent number: 7534509
    Abstract: Ambient-temperature molten salts of formula (I): wherein Y+ is a cation selected from the group consisting of an ammonium ion, a sulfonium ion, a pyridinium ion, a(n) (iso)thiazolium ion, and a(n) (iso)oxazolium ion that may be optionally substituted with C1-10 alkyl and/or C1-10 alkyl having ether linkage, provided that the above cation has at least one substituent of —CH2Rf1 or —OCH2Rf1 (wherein Rf1 is C1-10 perfluoroalkyl); Rf2 and Rf3 are independently C1-10 perfluoroalkyl or may together form C1-4 perfluoroalkylene; and X is —SO2— or —CO—.
    Type: Grant
    Filed: November 3, 2004
    Date of Patent: May 19, 2009
    Assignee: Toyota Jidosha Kabushiki Kaisha
    Inventor: Teruo Umemoto
  • Patent number: 7531576
    Abstract: Biphenyl derivatives represented by the following formula (1): wherein R1 represents a C5-7 alkyl group, R2 represents a substituted or unsubstituted aromatic hydrocarbon, or cycloalkyl group, R3 represents a tetrazolyl group, —NHCOCF3, —NHSO2CF3 or —SO2NHCONHR4 in which R4 represents a substituted or unsubstituted aromatic hydrocarbon group, and Z represents a single bond, a C1-4 alkylene group or —SO2NH—, and salts thereof; and ACAT inhibitors and medicines containing them as active ingredients. The compounds according to the present invention possess excellent ACAT inhibitory activities, and are useful as preventives and/or therapeutics for diseases cased by the enhancement of ACAT activity, for example, hypercholesterolemia, atherosclerosis and the like.
    Type: Grant
    Filed: December 5, 2001
    Date of Patent: May 12, 2009
    Assignee: Pola Chemical Industries, Inc.
    Inventors: Takayuki Namiki, Kenichi Kishii, Masaki Mitani, Masashi Tamai, Naoki Hiyama, Makoto Kimura, Satoshi Ichinomiya
  • Publication number: 20080293701
    Abstract: 1-Acylamino-2-hydroxy-3-amino-?-arylalkanes of formula I. and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive, medicinally active ingredients.
    Type: Application
    Filed: February 1, 2006
    Publication date: November 27, 2008
    Inventors: John J. Baldwin, David A. Claremon, Lawrence W. Dillard, Patrick T. Flaherty, Alexey V. Ishchenko, Jing Yuan, Zhenrong Xu, Gerard McGeehan, Wenguang Zeng, Salvacion Cacatian, Colin Tice, Robert D. Simpson, Wei Zhao
  • Publication number: 20080027245
    Abstract: A novel class of compounds that includes HPTS-Cys-MA, and methods of making them are disclosed herein. The class of compounds including HPTS-Cys-MA are useful as fluorescent dyes for analyte detection.
    Type: Application
    Filed: July 24, 2007
    Publication date: January 31, 2008
    Applicant: GluMetrics Inc.
    Inventor: Jeff T. Suri
  • Patent number: RE40861
    Abstract: Compounds of formula (I) wherein the groups are as defined in the description are disclosed. The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparation of medicaments useful in the pathologies related to a hyperactivity of carnitine palmitoyl-transferase, such as hyperglycemia, diabetes and pathologies related thereto, heart failure, ischemia.
    Type: Grant
    Filed: November 30, 2006
    Date of Patent: July 21, 2009
    Assignee: Sigma-Tau Industrie Farmaceutiche Reunite S.p.A.
    Inventors: Fabio Giannessi, Mauro Marzi, Patrizia Minetti, Francesco De Angelis, Maria O. Tinti, Piero Chiodi, Arduino Arduini